# LXN Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lxn

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Total disclosed funding: $22M
- Latest round: Series E (Apr 20, 1999)
- Investors on record: 11

## About

LXN Corporation is a medical technology company that focuses on the development of diabetes products.

## Funding rounds

- Series E, Apr 20, 1999, $10M — Advent International, Alta Partners, MedVenture Associates, MPM BioImpact, The Walden Group, Veron International, Premier Medical Partner Fund, Biotechnology Investment Fund
- Series D, Nov 21, 1997, $12M — Advent International, Alta Partners, InveStar Capital, The Walden Group, Maton Venture, Veron International, Microlife Investment, Biotechnology Investment Fund

## Investors

- Advent International (https://capitalatlas.ai/funds/advent-international) — Series D, Series E
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D, Series E
- InveStar Capital (https://capitalatlas.ai/funds/investar-capital) — Series D
- The Walden Group — Series D, Series E
- Maton Venture (https://capitalatlas.ai/funds/maton-venture) — Series D
- Veron International — Series D, Series E
- Microlife Investment — Series D
- Biotechnology Investment Fund — Series D, Series E
- MedVenture Associates (https://capitalatlas.ai/funds/medventure-associates) — Series E
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series E
- Premier Medical Partner Fund (https://capitalatlas.ai/funds/premier-medical-partner-fund) — Series E